Hypertension and Survival in Colorectal Cancer Patients Treated with Bevacizumab
Author Information
Author(s): Österlund P, Soveri L-M, Isoniemi H, Poussa T, Alanko T, Bono P
Primary Institution: Helsinki University Central Hospital
Hypothesis
Does hypertension predict treatment efficacy in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy?
Conclusion
Hypertension may predict the outcome of bevacizumab-containing chemotherapy in metastatic colorectal cancer patients.
Supporting Evidence
- 56% of patients developed grade 1 hypertension during treatment.
- Patients with hypertension had a median overall survival of 25.8 months compared to 11.7 months for normotensive patients.
- Hypertension was associated with improved progression-free survival of 10.5 months versus 5.3 months.
Takeaway
If cancer patients taking a specific treatment develop high blood pressure, it might mean the treatment is working better for them.
Methodology
101 patients with metastatic colorectal cancer were treated with chemotherapy and bevacizumab, with blood pressure monitored before each infusion.
Potential Biases
Potential biases due to the observational nature of the study and exclusion of patients with certain conditions.
Limitations
The study is retrospective and conducted at a single center, which may limit generalizability.
Participant Demographics
Median age was 59 years, with 53% male and 47% female participants.
Statistical Information
P-Value
p<0.001
Confidence Interval
CI95%: 19.2–32.4
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website